Used in cancer immunotherapy research, particularly for targeting neuroblastoma and other GD2-expressing tumors. Binds specifically to the GD2 disialoganglioside antigen found on the surface of neuroectodermal tumor cells. Enables targeted delivery of therapeutic agents or facilitates immune-mediated destruction of cancer cells through mechanisms like antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Serves as a reference standard in assay development, antibody engineering, and biosimilar studies to evaluate binding affinity, functional activity, and comparability of anti-GD2 therapeutic candidates. Supports preclinical and analytical testing in the development of monoclonal antibody treatments.